At the news
? NEUTRALIMPACT 2/10 S-3 filed Apr 3, 2026 at 16:23 ET
Lyell Immunopharma has filed an S-3 shelf registration to allow selling stockholders to resell 1,952,360 shares of common stock acquired in a private placement on March 6, 2026. The company will not receive any proceeds from these sales, which were originally purchased at $25.61 per share in a milestone closing. The registration enables liquidity for institutional investors including ARCH Venture Fund, Gates Frontier, and Explore Investments.
- S-3 filing registers 1,952,360 shares for resale by selling stockholders from a March 6, 2026 private placement
- Company will not receive any proceeds from the resale of these shares
- Shares were acquired at $25.61 per share in a milestone closing under a July 2025 Securities Purchase Agreement
- Selling stockholders include ARCH Venture Fund XIII, Euler Fund, Gates Frontier LLC, and Explore Investments LLC
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access